JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giusti, P.
Right arrow Articles by Guidotti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giusti, P.
Right arrow Articles by Guidotti, A.

The preferential antagonism of pentylenetetrazole proconflict responses differentiates a class of anxiolytic benzodiazepines with potential antipanic action

P Giusti, G Guidetti, E Costa and A Guidotti

Fidia-Georgetown Institute for the Neurosciences, Georgetown University, School of Medicine, Washington, DC.

With the use of the shock-induced suppression of water drinking in thirsty rats (Vogel's conflict paradigm) and the pentylenetetrazole- enhanced shock-induced suppression of drinking (proconflict paradigm) as animal models to test anxiolytic and antipanic agents, it was possible to distinguish two major classes of benzodiazepines (BZDs) and congeners on the basis of their antiproconflict index (ratio of anticonflict/antiproconflict potencies). Thus, typical low potency BZDs and congeners (diazepam, midazolam, zolpidem, alpidem) with anxiolytic/hypnotic properties have a low antiproconflict index (close to 1), whereas typical high potency BZDs (clonazepam, alprazolam, bretazenil) with reported antipanic properties have an antiproconflict index approximately 10-fold higher. The anticonflict and antiproconflict actions of BZDs with low or high antiproconflict indices are blocked by flumazenil but are potentiated differentially by the gamma-aminobutyric acid (GABA) reuptake blocker 1-2- [bis(trifluoromethyl)-phenyl]-methoxyethyl-1,2,5,6-tetrahydro-3- pyridine-carboxylic acid. Protracted administration of antianxiety and antipanic antidepressant drugs that do not act on GABAA receptors, directly, resulted in anticonflict and antiproconflict effects. However, the efficacy of these drugs is clearly inferior (20-30%) to that of BZDs. These data suggest that specific GABAA receptor subtypes mediate the pharmacological action of BZDs possessing low and high antiproconflict indices.

Volume 257, Issue 3, pp. 1062-1068, 06/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. Beekman, J. T. Ungard, M. Gasior, R. B. Carter, D. Dijkstra, S. R. Goldberg, and J. M. Witkin
Reversal of Behavioral Effects of Pentylenetetrazol by the Neuroactive Steroid Ganaxolone
J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 868 - 877.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1991 by the American Society for Pharmacology and Experimental Therapeutics.